Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications

International Journal of Biochemistry and Cell Biology

Volumn 42, Issue 8, 2010, Pages 1262-1272

  Mezzanzanica, Delia ^a   Bagnoli, Marina ^a   De Cecco, Loris ^a   Valeri, Barbara ^a   Canevari, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Diagnosis; MicroRNA; Ovarian cancer; Prognosis

Indexed keywords

B RAF KINASE; BETA CATENIN; BRCA1 PROTEIN; BRCA2 PROTEIN; DICER; MICRORNA; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; UVOMORULIN; TUMOR MARKER;

BIOGENESIS; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CHROMOSOME; CYTOPLASM; DNA BINDING; DNA METHYLATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENOME; HUMAN; LUNG NON SMALL CELL CANCER; OVARY CANCER; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN DOMAIN; REVIEW; SURVIVAL RATE; BIOSYNTHESIS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY;

FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77954382910     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2009.12.017     Document Type: Review

References (103)

1. Agarwal R., Kaye S.B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003, 3:502-516.
2. Ahmed N., Thompson E.W., Quinn M.A. Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. J Cell Physiol 2007, 213:581-588.
3. Aigner K., Dampier B., Descovich L., Mikula M., Sultan A., Schreiber M., et al. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 2007, 26:6979-6988.
4. Auersperg N., Wong A.S., Choi K.C., Kang S.K., Leung P.C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001, 22:255-288.
5. Bagnoli M., Balladore E., Luison E., Alberti P., Raspagliesi F., Marcomini B., et al. Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment. Mol Cancer Ther 2007, 6:762-772.
6. Balch C., Fang F., Matei D.E., Huang T.H., Nephew K.P. Minireview: epigenetic changes in ovarian cancer. Endocrinology 2009, 150:4003-4011.
7. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
8. Bast R.C., Hennessy B., Mills G.B. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009, 9:415-428.
9. Bearfoot J.L., Choong D.Y., Gorringe K.L., Campbell I.G. Genetic analysis of cancer-implicated microRNA in ovarian cancer. Clin Cancer Res 2008, 14:7246-7250.
10. Bendoraite A., Knouf E.C., Garg K.S., Parkin R.K., Kroh E.M., O'Briant K.C., et al. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol 2010, 1161:117-125.
11. Bild A.H., Potti A., Nevins J.R. Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer 2006, 6:735-741.
12. Bolos V., Peinado H., Perez-Moreno M.A., Fraga M.F., Esteller M., Cano A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci 2003, 116:499-511.
13. Boren T., Xiong Y., Hakam A., Wenham R., Apte S., Chan G., et al. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009, 113:249-255.
14. Breving K., Esquela-Kerscher A. The complexities of microRNA regulation: mirandering around the rules. Int J Biochem Cell Biol 2009, 10.1016/j.biocel.2009.09.016.
15. Bukholm I.K., Nesland J.M., Borresen-Dale A.L. Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients. J Pathol 2000, 190:15-19. [see comments].
16. Calin G.A., Ferracin M., Cimmino A., Di L.G., Shimizu M., Wojcik S.E., et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005, 353:1793-1801.
17. Canevari S., Gariboldi M., Reid J.F., Bongarzone I., Pierotti M.A. Molecular predictors of response and outcome in ovarian cancer. Crit Rev Oncol Hematol 2006, 60:19-37.
18. Chang T.C., Zeitels L.R., Hwang H.W., Chivukula R.R., Wentzel E.A., Dews M., et al. Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci USA 2009, 106:3384-3389.
19. Chen L.M., Yamada S.D., Fu Y.S., Baldwin R.L., Karlan B.Y. Molecular similarities between primary peritoneal and primary ovarian carcinomas. Int J Gynecol Cancer 2003, 13:749-755.
20. Cheng W., Liu J., Yoshida H., Rosen D., Naora H. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med 2005, 11:531-537.
21. Chim S.S., Shing T.K., Hung E.C., Leung T.Y., Lau T.K., Chiu R.W., et al. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 2008, 54:482-490.
22. Clarke-Pearson D.L. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009, 361:170-177.
23. Corney D.C., Nikitin A.Y. MicroRNA and ovarian cancer. Histol Histopathol 2008, 23:1161-1169.
24. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009, 10:704-714.
25. Cunningham J.M., Oberg A.L., Borralho P.M., Kren B.T., French A.J., Wang L.B., et al. Evaluation of a new high-dimensional miRNA profiling platform. BMC Med Genom 2009, 2:57.
26. Dahiya N., Sherman-Baust C.A., Wang T.L., Davidson B., Shih I., Zhang Y., et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 2008, 3:e2436.
27. Dahiya N., Morin P. MicroRNAs in ovarian carcinomas. Endocr Relat Cancer 2009, [Epub ahead of print. PMID: 19903743. PubMed - as supplied by publisher].
28. Davidson B. Ovarian carcinoma and serous effusions. Changing views regarding tumor progression and review of current literature. Anal Cell Pathol 2001, 23:107-128.
29. De Cecco L., Marchionni L., Gariboldi M., Reid J.F., Lagonigro M.S., Caramuta S., et al. Gene expression profiling of advanced ovarian cancer: characterization of molecular signature involving the fibroblast growth factor 2. Oncogene 2004, 23:8171-8183.
30. De Santis G., Miotti S., Mazzi M., Canevari S., Tomassetti A. E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells. Oncogene 2009, 28:1206-1217.
31. Donninger H., Bonome T., Radonovich M., Pise-Masison C.A., Brady J., Shih J.H., et al. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 2004, 23:8065-8077.
32. Dressman H.K., Berchuck A., Chan G., Zhai J., Bild A., Sayer R., et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007, 25:517-525.
33. Duan R., Feng Y., Ying M. Entanglement is not necessary for perfect discrimination between unitary operations. Phys Rev Lett 2007, 98:100503.
34. Duchaine T.F., Slack F.J. rna interference and micro rna-oriented therapy in cancer: rationales, promises, and challenges. Curr Oncol 2009, 16:61-66.
35. Eis P.S., Tam W., Sun L., Chadburn A., Li Z., Gomez M.F., et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 2005, 102:3627-3632.
36. Eitan R., Kushnir M., Lithwick-Yanai G., David M.B., Hoshen M., Glezerman M., et al. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol 2009, 114:253-259.
37. Esquela-Kerscher A., Slack F.J. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269.
38. Fabbri M., Garzon R., Cimmino A., Liu Z., Zanesi N., Callegari E., et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007, 104:15805-15810.
39. Farley J., Ozbun L.L., Birrer M.J. Genomic analysis of epithelial ovarian cancer. Cell Res 2008, 18:538-548.
40. Feeley K.M., Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001, 38:87-95.
41. Feng G., Li G., Gentil-Perret A., Tostain J., Genin C. Elevated serum-circulating RNA in patients with conventional renal cell cancer. Anticancer Res 2008, 28:321-326.
42. Foekens J.A., Sieuwerts A.M., Smid M., Look M.P., de W.V., Boersma A.W., et al. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA 2008, 105:13021-13026.
43. Garzon R., Calin G.A., Croce C.M. MicroRNAs in cancer. Annu Rev Med 2009, 60:167-179.
44. Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008, 10:593-601.
45. He L., He X., Lowe S.W., Hannon G.J. microRNAs join the p53 network-another piece in the tumour-suppression puzzle. Nat Rev Cancer 2007, 7:819-822.
46. Heintz A.P., Odicino F., Maisonneuve P., Quinn M.A., Benedet J.L., Creasman W.T., et al. Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006, 95(Suppl. 1):S161-S192.
47. Hu X., Macdonald D.M., Huettner P.C., Feng Z., El Naqa I., Schwarz J.K., et al. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 2009, 114:457-464.
48. Hu Z., Chen J., Tian T., Zhou X., Gu H., Xu L., et al. Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest 2008, 118:2600-2608.
49. Hwang H.W., Wentzel E.A., Mendell J.T. Cell-cell contact globally activates microRNA biogenesis. Proc Natl Acad Sci USA 2009, 106:7016-7021.
50. Iorio M.V., Visone R., Di Leva G., Donati V., Petrocca F., Casalini P., et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007, 67:8699-8707.
51. Jazaeri A.A., Yee C.J., Sotiriou C., Brantley K.R., Boyd J., Liu E.T. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 2002, 94:990-1000.
52. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
53. Konstantinopoulos P.A., Spentzos D., Cannistra S.A. Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol 2008, 5:577-587.
54. Korpal M., Lee E.S., Hu G., Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008, 283:14910-14914.
55. Kowalski L.D., Kanbour A.I., Price F.V., Finkelstein S.D., Christopherson W.A., Seski J.C., et al. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma. Cancer 1997, 79:1587-1594.
56. Kurman R.J., Shih I.e.M. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008, 27:151-160.
57. Laios A., O'Toole S., Flavin R., Martin C., Kelly L., Ring M., et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 2008, 7:35.
58. Landen C.N., Birrer M.J., Sood A.K. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008, 26:995-1005.
59. Lawrie C.H., Gal S., Dunlop H.M., Pushkaran B., Liggins A.P., Pulford K., et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008, 141:672-675.
60. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854.
61. Levanon K., Crum C., Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008, 26:5284-5293.
62. Lewis B.P., Shih I.H., Jones-Rhoades M.W., Bartel D.P., Burge C.B. Prediction of mammalian microRNA targets. Cell 2003, 115:787-798.
63. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
64. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
65. Lu L., Katsaros D., de la Longrais I., Sochirca O., Yu H. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res 2007, 67:10117-10122.
66. Markman M., Bookman M.A. Second-line treatment of ovarian cancer. Oncologist 2000, 5:26-35.
67. Marquez R.T., Baggerly K.A., Patterson A.P., Liu J., Broaddus R., Frumovitz M., et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 2005, 11:6116-6126.
68. Merritt W.M., Lin Y.G., Han L.Y., Kamat A.A., Spannuth W.A., Schmandt R., et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008, 359:2641-2650.
69. Mezzanzanica D., Balladore E., Turatti F., Luison E., Alberti P., Bagnoli M., et al. CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma. Clin Cancer Res 2004, 10:5202-5214.
70. Mirnezami A.H., Pickard K., Zhang L., Primrose J.N., Packham G. MicroRNAs: key players in carcinogenesis and novel therapeutic targets. Eur J Surg Oncol 2009, 35:339-347.
71. Nam E.J., Yoon H., Kim S.W., Kim H., Kim Y.T., Kim J.H., et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008, 14:2690-2695.
72. Nieto M.A. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 2002, 3:155-166.
73. Park S.M., Shell S., Radjabi A.R., Schickel R., Feig C., Boyerinas B., et al. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 2007, 6:2585-2590.
74. Park S.M., Gaur A.B., Lengyel E., Peter M.E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008, 22:894-907.
75. Pasquinelli A.E., Reinhart B.J., Slack F., Martindale M.Q., Kuroda M.I., Maller B., et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000, 408:86-89.
76. Peter M.E. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 2009, 8:843-852.
77. Potti A., Dressman H.K., Bild A., Riedel R.F., Chan G., Sayer R., et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006, 12:1294-1300.
78. Resnick K.E., Alder H., Hagan J.P., Richardson D.L., Croce C.M., Cohn D.E. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009, 112:55-59.
79. Rouhi A., Mager D.L., Humphries R.K., Kuchenbauer F. MiRNAs, epigenetics, and cancer. Mamm Genome 2008, 19:517-525.
80. Saito Y., Liang G., Egger G., Friedman J.M., Chuang J.C., Coetzee G.A., et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006, 9:435-443.
81. Sandercock J., Parmar M.K., Torri V. First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. Br J Cancer 1998, 78:1471-1478.
82. Shell S., Park S.M., Radjabi A.R., Schickel R., Kistner E.O., Jewell D.A., et al. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA 2007, 104:11400-11405.
83. Shih I.-M., Kurman R.J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004, 164:1511-1518.
84. Slack F.J., Basson M., Liu Z., Ambros V., Horvitz H.R., Ruvkun G. The lin-41 RBCC gene acts in the C. elegans heterochronic pathway between the let-7 regulatory RNA and the LIN-29 transcription factor. Mol Cell 2000, 5:659-669.
85. Slack F.J., Weidhaas J.B. MicroRNA in cancer prognosis. N Engl J Med 2008, 359:2720-2722.
86. Sorrentino A., Liu C.G., Addario A., Peschle C., Scambia G., Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008, 111:478-486.
87. Sundfeldt K., Piontkewitz Y., Ivarsson K., Nilsson O., Hellberg P., Brannstrom M., et al. E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int J Cancer 1997, 74:275-280.
88. Sundfeldt K. Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule. Mol Cell Endocrinol 2003, 202:89-96.
89. Suzuki H.I., Yamagata K., Sugimoto K., Iwamoto T., Kato S., Miyazono K. Modulation of microRNA processing by p53. Nature 2009, 460:529-533.
90. Takamizawa J., Konishi H., Yanagisawa K., Tomida S., Osada H., Endoh H., et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004, 64:3753-3756.
91. Taylor D.D., Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008, 110:13-21.
92. Visone R., Croce C.M. MiRNAs and cancer. Am J Pathol 2009, 174:1131-1138.
93. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006, 103:2257-2261.
94. Wyman S.K., Parkin R.K., Mitchell P.S., Fritz B.R., O'Briant K., Godwin A.K., et al. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One 2009, 4:e5311.
95. Yang H., Kong W., He L., Zhao J.J., O'Donnell J.D., Wang J., et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008, 68:425-433.
96. Yang N., Kaur S., Volinia S., Greshock J., Lassus H., Hasegawa K., et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 2008, 68:10307-10314.
97. Yap T.A., Carden C.P., Kaye S.B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009, 9:167-181.
98. Yekta S., Shih I.H., Bartel D.P. MicroRNA-directed cleavage of HOXB8 mRNA. Science 2004, 304:594-596.
99. Yekta S., Tabin C.J., Bartel D.P. MicroRNAs in the Hox network: an apparent link to posterior prevalence. Nat Rev Genet 2008, 9:789-796.
100. Yu S.L., Chen H.Y., Chang G.C., Chen C.Y., Chen H.W., Singh S., et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008, 13:48-57.
101. Zhang L., Huang J., Yang N., Greshock J., Megraw M.S., Giannakakis A., et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 2006, 103:9136-9141.
102. Zhang L., Volinia S., Bonome T., Calin G.A., Greshock J., Yang N., et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 2008, 105:7004-7009.
103. Zorn K.K., Jazaeri A.A., Awtrey C.S., Gardner G.J., Mok S.C., Boyd J., et al. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res 2003, 9:4811-4818.